ThromboGenics/Alcon's Jetrea gets strongest AMNOG endorsement yet from German HTA
This article was originally published in Scrip
Executive Summary
ThromboGenics/Alcon's Jetrea (ocriplasmin) for vitreomacular traction has won the strongest endorsement yet from German health technology appraisal institute IQWiG for a drug passing through the tough AMNOG pricing and reimbursement system. The institute thinks it offers "major" and "considerable" benefits over standard of care, which bodes well for the price that the firm will eventually be able to command in Germany.